Skip to Content


Active Substance: doripenem
Common Name: doripenem
ATC Code: J01DH04
Marketing Authorisation Holder: Janssen-Cilag International NV
Active Substance: doripenem
Status: Withdrawn
Authorisation Date: 2008-07-25
Therapeutic Area: Cross Infection Bacterial Infections Pneumonia, Bacterial Pneumonia, Ventilator-Associated Urinary Tract Infections
Pharmacotherapeutic Group: Antibacterials for systemic use

Therapeutic Indication

Doribax is indicated for the treatment of the following infections in adults:

  • nosocomial pneumonia (including ventilator-associated pneumonia);
  • complicated intra-abdominal infections;
  • complicated urinary tract infections.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The marketing authorisation for Doribax has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.